Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma Document date: 2018_8_30
ID: uzge50xu_37
Snippet: Study limitations included: 1) the open-label design, which could have affected results through the placebo effect; 2) measurements for both secondary outcomes (i.e., sEDN level and rescue medication usage) were done only 2 times, once at the beginning of the study for baseline and a second time at the end of the study, so it may have been more beneficial to measure serially; 3) patient recruitment was through a few different healthcare centers, .....
Document: Study limitations included: 1) the open-label design, which could have affected results through the placebo effect; 2) measurements for both secondary outcomes (i.e., sEDN level and rescue medication usage) were done only 2 times, once at the beginning of the study for baseline and a second time at the end of the study, so it may have been more beneficial to measure serially; 3) patient recruitment was through a few different healthcare centers, which may have introduced spectrum bias and affected study results; 4) no sample size calculation was done, so that the number of eligible patients for the study (n = 43) may have been too small to accurately assess the association between predictor (i.e., elevated sEDN and positive IgE for HDM) and outcome (significant improvement in ACD, sEDN and rescue medication following treatment).
Search related documents:
Co phrase search for related documents- baseline study and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- baseline study and open label design: 1, 2, 3, 4
- baseline study and patient recruitment: 1
- baseline study and placebo effect: 1, 2
- baseline study and result affect: 1
- baseline study and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- baseline study and secondary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- eligible patient and healthcare center: 1
- eligible patient and open label: 1, 2
- eligible patient and open label design: 1
- eligible patient and patient recruitment: 1
- eligible patient and sample size: 1, 2, 3
- eligible patient and secondary outcome: 1
- healthcare center and sample size: 1
- healthcare center and secondary outcome: 1
- open label and patient recruitment: 1, 2, 3, 4, 5, 6, 7, 8
- open label and placebo effect: 1, 2, 3, 4
- open label and rescue medication: 1, 2, 3, 4, 5
- open label and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date